Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions
Value in Health · 2023-03 · 26 (3) · 394-399
DOI: 10.1016/j.jval.2022.11.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2023-03. Verfasst von Sean D Sullivan. Beteiligte Einrichtung: The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA; Department of Health Policy, London School of Economics and Pol…. Hauptthemen laut MEDLINE: Medicare, Economic Competition. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
The United States is a relatively free-pricing market for pharmaceutical manufacturers to set list prices at the product launch. Few drug price controls exist, and federal price negotiation as a policy has historically been politically untenable. After decades of debate on whether the federal government, specifically the Medicare program, should more actively manage drug prices, the US Congress passed legislation authorizing Medicare to directly negotiate prices with manufacturers. The purpose of this article is to describe elements and implementation of the price negotiation provisions and then comment on the potential impacts on payers, innovations, and the pharmaceutical industry. While impacting only a few drugs each year in the beginning, price negotiation in the Medicare program will have secondary and long-term effects in the US market and beyond. It is clear that in the United States, the Medicare market for drugs will no longer be a free-pricing environment in the industry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA; Department of Health Policy, London School of Economics and Political Science, London, England, UK. Electronic address: sdsull@uw.edu.
Zitieren
APA
Sullivan, S. D. (2023). Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions. Value in Health, 26(3), 394-399. https://doi.org/10.1016/j.jval.2022.11.015
Vancouver
Sullivan SD. Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions. Value in Health. 2023;26(3):394-399. doi:10.1016/j.jval.2022.11.015
BibTeX
@article{Sullivan2023,
author = {Sullivan, Sean D},
title = {Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions},
journal = {Value in Health},
year = {2023},
volume = {26},
number = {3},
pages = {394--399},
doi = {10.1016/j.jval.2022.11.015}
}
EUVIMED